Pioglitazone and Losartan Provides Additional Renoprotection

This study has been completed.

Sponsor:

Information provided by:

Shanghai Jiao Tong University School of Medicine

ClinicalTrials.gov Identifier:

NCT00364988

First received: August 14, 2006

Last updated: NA

Last verified: January 2005

History: No changes posted

Tracking Information

First Received Date ^ICMJE

August 14, 2006

Last Updated Date

August 14, 2006

Start Date ^ICMJE

January 2005

Primary Completion Date

Not Provided

Current Primary Outcome Measures ^ICMJE

Not Provided

Original Primary Outcome Measures ^ICMJE

Not Provided

Change History

No Changes Posted

Current Secondary Outcome Measures ^ICMJE

Not Provided

Original Secondary Outcome Measures ^ICMJE

Not Provided

Current Other Outcome Measures ^ICMJE

Not Provided

Original Other Outcome Measures ^ICMJE

Not Provided

Descriptive Information

Brief Title ^ICMJE

Pioglitazone and Losartan Provides Additional Renoprotection

Official Title ^ICMJE

Combination Therapy With Pioglitazone and Losartan Provides Additional Renoprotection in Subjects With Type 2 Diabetic Nephropathy

Brief Summary

Peroxisomal proliferator-activated receptor agonist pioglitazone and rosiglitazone are currently used in the treatment of type 2 diabetes, as efficient insulin sensitizers alone or in combination with insulin.angiotensin II receptor antagonist losartan reduced the levels of proteinuria.Whether Combination therapy with pioglitazone and losartan provides additional renoprotection in subjects with type 2 diabetic nephropathy,it's worth researching.

Detailed Description

Not Provided

Study Type ^ICMJE

Interventional

Study Phase

Not Provided

Study Design ^ICMJE

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Condition ^ICMJE

Type 2 Diabetes
Diabetic Nephropathy

Intervention ^ICMJE

Drug: pioglitazone
Drug: losartan

Study Arm (s)

Not Provided

Publications *

Not Provided

* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.

Recruitment Information

Recruitment Status ^ICMJE

Completed

Enrollment ^ICMJE

Completion Date

Not Provided

Primary Completion Date

Not Provided

Eligibility Criteria ^ICMJE

Inclusion Criteria:

Fasting plasma glucose (FPG) level of 3.3-9.0mmol/L
2h plasma glucose level of 7.5-13 mmol/L
serum creatinine values between 190 and 660umol/L
Two occasions of a ratio of urinary albumin to urinary creatinine≥300 or 24 hours urinary protein concentration is ＞150mg
Informed consent

Exclusion Criteria:

Type1 diabetes or nondiabetic renal disease
abnormal liver function
heart dysfunction

Gender

Both

Ages

32 Years to 75 Years

Accepts Healthy Volunteers

Contacts ^ICMJE

Contact information is only displayed when the study is recruiting subjects

Location Countries ^ICMJE

Not Provided

Administrative Information

NCT Number ^ICMJE

NCT00364988

Other Study ID Numbers ^ICMJE

PLAN

Has Data Monitoring Committee

Not Provided

Responsible Party

Not Provided

Study Sponsor ^ICMJE

Shanghai Jiao Tong University School of Medicine

Collaborators ^ICMJE

Not Provided

Investigators ^ICMJE

Principal Investigator:

Hui M Jin, MD

Shanghai No.3 People's Hospital

Information Provided By

Shanghai Jiao Tong University School of Medicine

Verification Date

January 2005

^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP

To Top